ClinicalTrials.gov
ClinicalTrials.gov Menu

fMRI Cholinergic Mechanisms in Schizophrenia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01191827
Recruitment Status : Completed
First Posted : August 31, 2010
Results First Posted : May 15, 2015
Last Update Posted : May 15, 2015
Sponsor:
Information provided by (Responsible Party):
VA Office of Research and Development ( US Department of Veterans Affairs )

August 27, 2010
August 31, 2010
December 23, 2014
May 15, 2015
May 15, 2015
October 2008
December 2011   (Final data collection date for primary outcome measure)
Neuronal Response During Sensory Gating [ Time Frame: Immediate ]
Neuronal response (blood oxygenation level dependent functional magnetic resonance imaging signal, relative to the global mean) during sensory gating. Sensory gating is defined as the process of filtering out unnecessary environmental stimuli.
Neuronal Response During Sensory Gating [ Time Frame: Immediate ]
Complete list of historical versions of study NCT01191827 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
fMRI Cholinergic Mechanisms in Schizophrenia
fMRI Cholinergic Mechanisms in Schizophrenia
This study aims to determine how clozapine treatment improves neuronal measures of sensory gating in subjects with schizophrenia.
This study will use functional magnetic resonance imaging (fMRI) to study patients treated with risperidone, a commonly used neuroleptic that does not improves sensory gating, to those treated with clozapine to determine which brain areas are involved in clozapine's normalization of sensory gating in schizophrenia.
Observational
Observational Model: Cohort
Time Perspective: Cross-Sectional
Not Provided
Not Provided
Non-Probability Sample
Subjects with schizophrenia
Schizophrenia
Not Provided
  • risperidone
  • clozapine
    Patients with schizophrenia treated with clozapine
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
40
Same as current
December 2011
December 2011   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Diagnosis of schizophrenia
  • age 18-60 yrs

Exclusion Criteria:

  • claustrophobia
  • weight > 250 lbs
  • metal in body other than dental fillings
Sexes Eligible for Study: All
18 Years to 60 Years   (Adult)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT01191827
MHBB-011-07F
Yes
Not Provided
Not Provided
VA Office of Research and Development ( US Department of Veterans Affairs )
US Department of Veterans Affairs
Not Provided
Principal Investigator: Jason R. Tregellas, PhD VA Eastern Colorado Health Care System, Denver
VA Office of Research and Development
May 2015